Expression And Clinical Significance Of Transcription Factor Sp1 And EZH2 In Renal Cell Carcinoma

Objective:To investigate the expressions of transcription factor Spl and EZH2 in renal cell carcinomas and the relations with the pathological grades and clinical stages.Methods:68 cases of renal cell carcinomas and 15 cases of carcinoma-adjacent who underwent radical nephrectomy during the time of January 2013 to January 2016 in yanbian university hospital were involved in this study.The immunohistochemical method was used to detect the expressions of Spl and EZH2.Results:1.The positive expression of Spl and EZH2 in renal cell carcinoma was 72.06%and 70.59%,and the positive expression of Spl and EZH2 in cancer tissue rates were 20%and 13.33%,the positive expression of renal cell carcinoma and peficancerous tissues were significantly different(P>0.05).2.The expressions of Spl in high and middle differentiation group was 62.22%,but in low differentiation group was 91.30%.The expressions of Spl in Stage T1-2 and Stage T3-4 were 59.37%and 83.33%,respectively.3.The expressions of EZH2 in high and middle differentiation groups was 57.78%,but in low differentiation group was 95.65%.The expressions of EZH2 in Stage T1-2 and Stage T3-4 were 53.13%and 86.11%,respectively.4.The correlation existed between expressions of Spl and EZH2 in renal cell carcinomas.(r2=0.245,P=0.044)Conclusions:The expression of transcription factor Spl and EZH2 was related with the pathological features of renal cell carcinoma and its relationship with clinical stage,and may be together promote the occurrence and development of renal cell carcinoma.They might be used as a new biomarker to predict the disease progression and prognosis,and Is expected to become a new strategy for renal cell carcinoma targeted therapy.